Ground-breaking Alzheimer’s drug may be ‘beginning of the end’ for disease

Findings of a phase-three clinical trial confirm it slows cognitive decline by 27 per cent in sufferers

The Telegraph | I+D | Salud |

Leer noticia completa en el medio original
Spanish